These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 18457527

  • 21. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 22. New oral drugs for multiple sclerosis.
    Gasperini C, Ruggieri S.
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [Abstract] [Full Text] [Related]

  • 23. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V.
    Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
    [Abstract] [Full Text] [Related]

  • 24. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Mann H.
    N Engl J Med; 2010 May 06; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
    [No Abstract] [Full Text] [Related]

  • 25. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S, von Andrian UH.
    N Engl J Med; 2006 Sep 14; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Sep 14; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 32. Fingolimod for the treatment of relapsing multiple sclerosis.
    Singer BA.
    Expert Rev Neurother; 2013 Jun 14; 13(6):589-602. PubMed ID: 23738997
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A.
    J Pharmacol Exp Ther; 2007 Nov 14; 323(2):469-75. PubMed ID: 17682127
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
    Hu Y, Lee X, Ji B, Guckian K, Apicco D, Pepinsky RB, Miller RH, Mi S.
    Mol Cell Neurosci; 2011 Sep 14; 48(1):72-81. PubMed ID: 21740973
    [Abstract] [Full Text] [Related]

  • 39. [Fingolimod - a new immunomodulator].
    Friedrich FW, Eschenhagen T.
    Dtsch Med Wochenschr; 2009 Oct 14; 134(42):2127-31. PubMed ID: 19809964
    [Abstract] [Full Text] [Related]

  • 40. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.